GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » ROE % Adjusted to Book Value

INKT (MiNK Therapeutics) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 2021. Start your Free Trial

What is MiNK Therapeutics ROE % Adjusted to Book Value?

MiNK Therapeutics's ROE % for the quarter that ended in Dec. 2024 was 0.00%. MiNK Therapeutics's PB Ratio for the quarter that ended in Dec. 2024 was N/A. MiNK Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.

MiNK Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for MiNK Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiNK Therapeutics ROE % Adjusted to Book Value Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - - - -

MiNK Therapeutics Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of MiNK Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, MiNK Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's ROE % Adjusted to Book Value falls into.


;
;

MiNK Therapeutics ROE % Adjusted to Book Value Calculation

MiNK Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

MiNK Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of MiNK Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

MiNK Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiNK Therapeutics Inc (NAS:INKT) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
SRZN KZR RNXT OSTX KPTI ALXO RNTX KALA CVKD FBLG VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
Website
https://www.minktherapeutics.com
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Executives
Agenus Inc 10 percent owner 3 FORBES ROAD, LEXINGTON MA 02421
Garo H Armen director 3 FORBES ROAD, LEXINGTON MA 02421
Ulf Wiinberg director
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Christine M Klaskin officer: Treasurer 3 FORBES ROAD, LEXINGTON MA 02421
Jennifer Buell director, officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Barbara Ryan director 22 CAVRAY ROAD, NORWALK CT 06855
Walter Md Flamenbaum director 3 FORBES ROAD, LEXINGTON MA 02421
John Baldoni director 3 FORBES ROAD, LEXINGTON MA 02421
Peter Behner director 3 FORBES ROAD, LEXINGTON MA 02421
Van Dijk Marcus Antonius officer: Chief Technology Officer 149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010